Latest News and Press Releases

Trial opened for patient enrollment in the United States Independent Data Monitoring Committee recommends continuation of the trial as planned LYON, France and CAMBRIDGE, Mass., Nov. 04, 2019 ...

LYON, France et CAMBRIDGE, Mass., 20 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), société biopharmaceutique de stade clinique qui développe des thérapies...

LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies...

LIONE, Francia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), una società biofarmaceutica di fase clinica che sviluppa terapie innovative incapsulando...

LYON, Frankreich, Sept. 13, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), ein in der klinischen Entwicklungsphase tätiges Biopharma-Unternehmen, das innovative...

LYON, France, 13 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext : ERYP – Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant...

LYON, France, Sept. 13, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...

Conférence téléphonique et webcast : mardi 11 septembre à 14h30 Confirmation du virage stratégique entrepris vers le développement d’eryaspase dans les tumeurs solidesLancement de l’étude de Phase...

Conference call and webcast scheduled for Tuesday, September 11that 2:30 pm CET/8:30 am EDT Strategic shift to development of eryaspase for solid tumors confirmedPhase 3 trial for eryaspase in second...

LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic...